Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Provided written informed consent at screening.~* Diagnosed with type 2 diabetes mellitus.~* Glycosylated hemoglobin (A1c) \>7.0% and ≤8.5% at screening.~* Male or female ≥18 years of age.~* Women of childbearing potential must have been using an adequate method of contraception to avoid pregnancy throughout the study, and for up to 4 weeks after study completion.~* Fasting C-peptide level \>0.5 ng/mL at screening.~* Currently being treated with a stable dose of an approved non-thiazolidinedione antihyperglycemic medication (including sulfonylureas, meglitinides, insulin secretagogues, metformin, or α-glucosidase inhibitors) given as monotherapy, for at least 3 months prior to screening, and could discontinue that antihyperglycemic medication at Visit 2 (Week -2) and for the duration of the study. OR~* Untreated and had not taken any antihyperglycemic agent during the 2 months prior to screening; if not treated with an oral antihyperglycemic agent, the participant was considered by the investigator to have failed diet and exercise modification as the sole treatment for type 2 diabetes mellitus.~* Clinically stable in regard to medical conditions other than type 2 diabetes mellitus.~* Concomitant medications (other than oral antihyperglycemic agents) were at stable doses for at least 30 days prior to enrollment and were not anticipated to need adjustment during the study period.~Exclusion Criteria:~* History of type 1 diabetes and/or history of ketoacidosis.~* History of long-term (\>2 months) therapy with insulin.~* History of prior treatment failure with, or intolerance of, a thiazolidinedione (ie, rosiglitazone, troglitazone, or pioglitazone).~* Treatment with a fibrate lipid-lowering agent (eg, fenofibrate, gemfibrozil).~* Confirmed repeat fasting glucose (≥2 readings of fasting blood glucose) \>240 mg/dL (13.3 mmol/L) during the 2-week washout/stabilization and placebo run-in period (Period A).~* Body mass index (BMI) \>45 kg/m2 at screening.~* History of weight loss \>10% over the 3 months prior to screening.~* Female participant who was pregnant or breastfeeding.~* Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure~  ≥110 mmHg.~* Any known history of congestive heart failure prior to screening.~* History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening. History of malignancy (except participants who had been disease-free for \>10 years), or whose malignancy was a basal or squamous cell skin carcinoma. Any history of bladder cancer was an exclusion from participation. Women with a history of cervical dysplasia (CIN2 or higher) were to be excluded unless 2 consecutive normal cervical smears had subsequently been recorded prior to enrollment.~* Impaired liver function including evidence of acute or chronic hepatitis or liver disease by medical history, clinical signs or symptoms, or laboratory results.~* Evidence for ongoing infectious liver disease with positive hepatitis A antigen or immunoglobulin M antibody, hepatitis B surface antigen, or antibodies to hepatitis C virus. Participants with normal liver function tests and isolated positive antibodies to hepatitis B virus could have been included.~* Known (or evidence of) infection with human immunodeficiency virus.~* Known hemoglobinopathy or chronic anemia that required specific treatment within 5 years of the screening visit.~* History of alcohol or drug abuse within 1 year prior to screening.~* History of unstable major psychiatric disorders. Known or suspected allergy or hypersensitivity to thiazolidinedione agents.~* Clinically significant abnormalities in any pre-randomization laboratory analyses that, in the investigator's opinion, comprised an undue risk with the participant's participation, or could potentially confound results of the study.~Unexplained hematuria (\>3 red blood cells per high-powered field by urine microscopy).~* Blood donation of ≥1 pint (0.5 liter) within the past 30 days prior to screening or plasma donation within 7 days prior to the screening visit (Visit 1).~* Prior known or possible exposure to rivoglitazone.~* Contraindication to treatment with pioglitazone once daily.~* Known or suspected allergy, hypersensitivity, or intolerance to the excipients of the investigational study medication.~* Participation in an interventional medical, surgical, or pharmaceutical study within 30 days prior to the screening visit (Visit 1).~* Any condition or concomitant therapy that, in the opinion of the investigator, might have posed a risk to the participant or made participation not in the participant's best interest.~* A direct or familial relationship with the Sponsor, investigator, or site personnel affiliated with the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): rivoglitazone HCl 0.5mg
- 2 (Type: EXPERIMENTAL): rivoglitazone HCl 1.0 mg
- 3 (Type: EXPERIMENTAL): rivoglitazone HCl 1.5 mg
- 4 (Type: PLACEBO_COMPARATOR): placebo matching rivoglitazone HCl tablets
- 5 (Type: ACTIVE_COMPARATOR): pioglitazone HCl 15 mg
- 6 (Type: ACTIVE_COMPARATOR): pioglitazone HCl 30 mg
- 7 (Type: ACTIVE_COMPARATOR): pioglitazone HCl 45 mg
- 8 (Type: PLACEBO_COMPARATOR): matching placebo for pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).